Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.18 USD | +1.46% | -3.02% | -39.04% |
04-26 | European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.4% | MT |
04-17 | Evaxion Announces Phase 2 Clinical Trial Update | CI |
Business Summary
Number of employees: 49
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Artificial Intelligence-Immunology Powered Vaccines
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Denmark
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Andreas Mattsson
FOU | Founder | - | 10/08/08 |
Niels Møller
FOU | Founder | 46 | 10/08/08 |
Chief Executive Officer | 52 | 28/08/23 | |
Director of Finance/CFO | 54 | 13/03/22 | |
Birgitte Rono
CTO | Chief Tech/Sci/R&D Officer | 47 | 31/08/17 |
Sabine Mølleskov
IRC | Investor Relations Contact | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 54 | 31/12/17 | |
Lars Holtug
BRD | Director/Board Member | 66 | 24/05/21 |
Marianne Søgaard
CHM | Chairman | 56 | 31/12/17 |
Niels Møller
FOU | Founder | 46 | 10/08/08 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 37,897,780 | 31,606,749 ( 83.40 %) | 0 | 83.40 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.04% | 22.62M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- EVAX Stock
- Company Evaxion Biotech A/S